Yearlong Hormone Therapy Refills Would Be Covered

Summary#

A-5787 is an introduced bill that would add requirements to New Jersey’s health coverage and Medicaid laws. It would require coverage for certain hormone therapy refills; its stated goal is to authorize that coverage. It has not become law, and the supplied materials do not include the current text of the laws it would supplement, so I could not verify how much of this coverage is already required.

  • Carrier health plans and State Health Benefits Commission and School Employees’ Health Benefits Commission contracts would have to cover a 12-month refill of qualifying hormone therapy that does not need refrigeration.
  • For a covered controlled substance, those plans and contracts would have to provide the maximum refill allowed at one time under state and federal law.
  • Medicaid would have to provide qualifying 12-month refills without cost-sharing (the person’s share of the cost). For controlled substances, it would have to allow the maximum refill permitted by law.
  • The definition covers FDA-approved drugs used to medically suppress, increase, or replace hormones the body is not producing at intended levels. It excludes GLP-1 drugs and GLP-1 receptor agonists.
  • The bill allows limits in the last quarter of a plan year if a 12-month supply has already been dispensed. It also allows temporary limits during an acute dispensing shortage.

What it means for you#

  • People with covered health plans: If your prescription meets the bill’s definition and does not need refrigeration, your plan would have to cover a 12-month refill. The bill does not require coverage of refrigerated therapy under this rule.
  • Medicaid members: A qualifying 12-month refill would have to be provided with no cost-sharing. The bill does not say that this no-cost-sharing rule applies to every refill or every hormone therapy prescription.
  • People using controlled substances: The refill available at one time would be capped at the maximum allowed by state and federal law; the bill does not set a separate amount.
  • Prescribing providers and plans: For plans, drug-use management rules may still apply where the bill and other laws allow. A provider may temporarily limit a plan-covered refill to 90 days during an acute shortage, and must rescind that limit at the first opportunity once a regular, sustainable supply returns.
  • Other residents: The bill does not directly change hormone therapy coverage for people whose coverage is outside the plans and Medicaid it names.

Money#

No publicly available information on the bill’s expected public or private cost.

  • The bill would require Medicaid to provide qualifying refills without cost-sharing, but gives no estimate of Medicaid spending.
  • It gives no estimate of costs to health plans or state and school employee benefit contracts. Any effects on premiums or other spending are also not stated.

What is unclear#

  • The current laws being supplemented were not supplied, so it is unclear what coverage duties already exist and what would be new.
  • The bill does not define “acute dispensing shortage,” “sustainable supply,” or “intended levels.”
  • It does not set a process for handling refill requests, disputes, or appeals, or require reporting on the new coverage.
  • For Medicaid, the shortage provision allows a temporary limit but does not say who may impose it. The bill also does not specify a separate start date for Medicaid; it says the act takes effect immediately and ties the plan and contract rules to issuance or renewal after enactment.

Case for#

  • The bill appears intended to make longer refills available for qualifying hormone therapy, which could reduce the need for repeated refills.
  • A 12-month refill may help maintain access for people whose treatment is stable and whose medication does not need refrigeration.
  • The shortage exception allows temporary limits when supply is acutely disrupted, rather than requiring the full refill in that circumstance.
  • Removing cost-sharing for qualifying Medicaid refills could reduce the amount Medicaid members pay for them.

Case against#

  • A 12-month refill requirement could increase costs for plans or Medicaid, but the bill provides no estimate of that effect.
  • Plans may still use drug-utilization management strategies, so the bill does not remove all possible restrictions on covered prescriptions.
  • The shortage exception uses undefined terms and does not spell out who decides when a shortage begins or ends, especially for Medicaid.
  • Without the current law text or details on appeals and oversight, readers cannot tell how the new requirements would fit with existing coverage rules.